Sign In
Buy STRO
$26.09
-2.59 (-9.03%)
At Close: Jun 05, 2026
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
04:05pm, Thursday, 14'th May 2026
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of who
Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices except the Nasdaq end lower, with the Nasdaq closing virtually unch
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful,
Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade
01:00am, Saturday, 18'th Apr 2026
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after Citizens Jmp raised their price target on the stock from $23.00 to $35.00. Citizens Jmp currently h
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
09:36am, Wednesday, 08'th Apr 2026
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
04:05pm, Monday, 23'rd Mar 2026
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Hold” from Analysts
03:12am, Wednesday, 18'th Mar 2026
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "Hold" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Two equiti
Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
08:57am, Friday, 13'th Mar 2026
Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-month rally. STRO's pipeline centers on next-generation ADCs, with lead candidate STRO-004 in Phase 1 an
Sutro Biopharma to Participate in Upcoming Investor Conferences
08:30am, Wednesday, 25'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
08:25am, Wednesday, 11'th Feb 2026
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
07:00am, Tuesday, 10'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?
07:16am, Thursday, 22'nd Jan 2026
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:46pm, Thursday, 15'th Jan 2026
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts
01:38am, Friday, 02'nd Jan 2026
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of "Hold" by the eight analysts that are presently covering the stock, MarketBeat.com reports. Two equi
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages
01:28am, Monday, 08'th Dec 2025
Shares of Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) have received a consensus recommendation of "Hold" from the eight research firms that are currently covering the stock, MarketBeat repo
